Healthcare strategy and communications agency

As a private equity partner, the Vespa Capital team have delivered what was promised when we started on this part of our journey with them; helping us to professionalise and scale, being supportive, considerate and adding expert knowledge when needed, in a highly collaborative manner”.

Lee Hurley, CEO at Cognite

Business Profile

Cognite is an independent healthcare strategy and communications agency that partners with an impressive roster of specialist pharmaceutical and biotech clients to help them ‘bring science to life’.

The business has built a leading position supporting biopharma companies with the launch of novel, highly complex therapies in niche and poorly understood rare and orphan disease therapeutic areas. Cognite supports its clients in healthcare strategy, medical affairs, creative/scientific messaging, digital and omnichannel campaigns, commercialisation, training, and patient engagement.

Through their combination of deep scientific and creative expertise, Cognite distils and conveys complex medical information to difficult to reach patient and HCP stakeholders supported by a digital-first proposition and multichannel offering.

Vespa Capital exited its investment in Cognite through a sale to Blue Matter Consulting in October 2026.

Visit Cognite

Status: Realised
Exited: October 2026
FTE growth: 3x
Sector: Life Sciences

Investment Summary

Vespa Capital exited Cognite in October 2026 following the sale to Blue Matter, Inc, a Baird Capital portfolio company. During the investment, Vespa Capital supported Cognite through expansion into the USA via a new subsidiary and investing in the development of a medical affairs offering, as well as the professionalisation of the core platform. Other investment highlights included:

Establishment of USA trading entity and continued growth in the USA market expanding to c.58% of Group revenue
Strongly outperformed the broader medcomms market as a result of science-first approach and data-led articulation
Enhancing business development capabilities and empowering second tier management to win new clients
Investment into new ERP and resource management system
Effective integration of medical and commercial expertise enabling larger share of wallet and pivot towards medical affairs.
Became “Agency of Record” across an expanding base of key biopharma accounts
Adoption and development of in-house AI tools to drive productivity

What our clients say

As a private equity partner, the Vespa Capital team have delivered what was promised when we started on this part of our journey with them; helping us to professionalise and scale, being supportive, considerate and adding expert knowledge when needed, in a highly collaborative manner